CD150-mediated Akt signalling pathway in normal and malignant B cells

Aim of this article is to study upstream and downstream events in CD150-mediated Akt signaling pathway in normal human B cells, EBV-transformed lymphoblastoid (LCL) and malignant Hodgkin’s lymphoma (HL) B cell lines

PIMECROLIMUS CREAM IN CLINICAL PRACTICE OF CHILDREN'S ALLERGOLOGIST IMMUNOLOGIST

The object of the investigation was to estimate the basic therapy of atopic dermatitis (ad) in children and to analyze pimecrolimus application in clinical practice of children's allergologists immunologist. A multi centered retrospective study analysis involving 360 children aged 0–17 with atopic dermatitis of different severity was carried out. Insufficient effectiveness of implementation of main points of national program «atopic dermatitis and skin infections in children: diagnostics, treatment and prophylaxis» is determined. 37,4% cases of discrepancies in diagnoses by severity of atopic dermatitis in case of physician evaluation and on the scale of SCORAD, low level of control over blood pressure and high usage of systemic corticosteroids are registered. The application of pimecrolimus is revealed in 11,3% patients. It is essential to use more extensively the strategy of prolonged anti-inflammatory therapy of ad, including pimecrolimus use.Key words: atopic dermatitis, pharmacotherapy, pimecrolimus, children, treatment

PIMECROLIMUS CREAM IN CLINICAL PRACTICE OF CHILDREN'S ALLERGOLOGIST IMMUNOLOGIST

The object of the investigation was to estimate the basic therapy of atopic dermatitis (ad) in children and to analyze pimecrolimus application in clinical practice of children's allergologists immunologist. A multi centered retrospective study analysis involving 360 children aged 0–17 with atopic dermatitis of different severity was carried out. Insufficient effectiveness of implementation of main points of national program «atopic dermatitis and skin infections in children: diagnostics, treatment and prophylaxis» is determined. 37,4% cases of discrepancies in diagnoses by severity of atopic dermatitis in case of physician evaluation and on the scale of SCORAD, low level of control over blood pressure and high usage of systemic corticosteroids are registered. The application of pimecrolimus is revealed in 11,3% patients. It is essential to use more extensively the strategy of prolonged anti-inflammatory therapy of ad, including pimecrolimus use.Key words: atopic dermatitis, pharmacotherapy, pimecrolimus, children, treatment

АЛЛЕРГИЧЕСКИЙ РИНИТ

.(Педиатрическая фармакология. – 2008;5(4):81-87

ПИМЕКРОЛИМУС КРЕМ В КЛИНИЧЕСКОЙ ПРАКТИКЕ ДЕТСКОГО АЛЛЕРГОЛОГА-ИММУНОЛОГА

The object of the investigation was to estimate the basic therapy of atopic dermatitis (ad) in children and to analyze pimecrolimus application in clinical practice of children's allergologists immunologist. A multi centered retrospective study analysis involving 360 children aged 0–17 with atopic dermatitis of different severity was carried out. Insufficient effectiveness of implementation of main points of national program «atopic dermatitis and skin infections in children: diagnostics, treatment and prophylaxis» is determined. 37,4% cases of discrepancies in diagnoses by severity of atopic dermatitis in case of physician evaluation and on the scale of SCORAD, low level of control over blood pressure and high usage of systemic corticosteroids are registered. The application of pimecrolimus is revealed in 11,3% patients. It is essential to use more extensively the strategy of prolonged anti-inflammatory therapy of ad, including pimecrolimus use.Key words: atopic dermatitis, pharmacotherapy, pimecrolimus, children, treatment.Целью исследования была оценка базисной терапии атопического дерматита у детей и анализ применения пимекролимуса в клинической практике детского иммунолога-аллерголога. Проведено многоцентровое ретроспективное исследование, в которое включены 360 детей, больных атопическим дерматитом разной степени тяжести, в возрасте от 0 до 17 лет. Установлено недостаточное внедрение основных положений Национальной программы «Атопический дерматит и инфекции кожи у детей: диагностика, лечение и профилактика». Зарегистрировано 37,4% случаев расхождения диагноза по степени тяжести атопического дерматита в случае оценки врачом и по шкале SCORAD, низкий уровень контроля над течением заболевания и высокая частота использования системных глюкокортикоидов. Пимекролимус применяли у 11,3% больных. Необходимо более широкое внедрение стратегии долговременной противовоспалительной терапии атопического дерматита, в том числе с применением пимекролимуса.Ключевые слова: атопический дерматит, фармакотерапия, пимекролимус.(Педиатрическая фармакология. – 2006; 3(3): 16-20